Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
IgG ATAC
- Development stage
- Preclinical
- Lead developer
- Avilar Therapeutics
- Modality
- PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Administration
- Oral
01
Overview
IgG ATAC is an oral small molecule heterobifunctional protein degrader developed by Avilar Therapeutics for the treatment of IgG-driven autoimmune diseases. It is the lead candidate from Avilar's proprietary ATAC (Antibody-Targeted Autologous Cell) platform, which is designed to target and degrade extracellular proteins. The molecule functions by simultaneously binding to circulating Immunoglobulin G (IgG) and the asialoglycoprotein receptor (ASGPR) expressed on the surface of hepatocytes. This dual engagement triggers the endocytosis of the IgG-ATAC complex into the liver cell, where it is trafficked to the lysosome for degradation. By selectively reducing the levels of pathogenic autoantibodies in the blood, IgG ATAC offers a novel therapeutic approach for a variety of autoimmune conditions mediated by IgG, such as myasthenia gravis and CIDP.
- Other names
- immunoglobulin G antibody-targeted amanitin conjugateIgG-ATACimmunoglobulin G antibody-targeted autologous cell degrader
02
Targets
ASGPR (Asialoglycoprotein Receptor 1)IgG Fc (Immunoglobulin G Fc region)
Beyond the preview
Go deeper on IgG ATAC.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on IgG ATAC.